Daniel Jerico
Overview
Explore the profile of Daniel Jerico including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
146
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fontanellas A, Berraondo P, Urigo F, Jerico D, Martini P, Pastor F, et al.
Gut
. 2025 Feb;
PMID: 39988358
RNA-based therapeutics have rapidly emerged over the past decade, offering a new class of medicines that differ significantly from conventional drugs. These therapies can be programmed to target or restore...
2.
Cordoba K, Jerico D, Jiang L, Collantes M, Alegre M, Garcia-Ruiz L, et al.
Gut
. 2024 Oct;
74(2):270-283.
PMID: 39366725
Objective: Acute intermittent porphyria (AIP) is a rare metabolic disorder caused by haploinsufficiency of hepatic porphobilinogen deaminase (PBGD), the third enzyme of the heme biosynthesis. Individuals with AIP experience neurovisceral...
3.
Jerico D, Cordoba K, Urigo F, Enriquez de Salamanca R, Anderson K, Deybach J, et al.
Liver Int
. 2024 May;
44(9):2174-2190.
PMID: 38813953
Porphyrias are rare, mostly inherited disorders resulting from altered activity of specific enzymes in the haem synthesis pathway that lead to accumulation of pathway intermediates. Photocutaneous symptoms occur when excess...
4.
Longo M, Paolini E, Meroni M, Jerico D, Cordoba K, Battistin M, et al.
Cell Mol Gastroenterol Hepatol
. 2023 Nov;
17(3):511-514.
PMID: 37979725
No abstract available.
5.
Longo M, Jerico D, Cordoba K, Riezu-Boj J, Urtasun R, Solares I, et al.
Int J Mol Sci
. 2023 Aug;
24(15).
PMID: 37569315
Acute intermittent porphyria (AIP) is a metabolic disorder caused by mutations in the porphobilinogen deaminase (PBGD) gene, encoding the third enzyme of the heme synthesis pathway. Although AIP is characterized...
6.
Solares I, Jerico D, Cordoba K, Morales-Conejo M, Ena J, Enriquez de Salamanca R, et al.
Int J Mol Sci
. 2023 Jan;
24(1).
PMID: 36613492
Porphobilinogen deaminase (PBGD) haploinsufficiency (acute intermittent porphyria, AIP) is characterized by neurovisceral attacks associated with high production, accumulation and urinary excretion of heme precursors, δ-aminolevulinic acid (ALA) and porphobilinogen (PBG)....
7.
Jerico D, Cordoba K, Sampedro A, Jiang L, Joucla G, Cabanne C, et al.
Life (Basel)
. 2022 Nov;
12(11).
PMID: 36430993
Rare diseases, especially monogenic diseases, which usually affect a single target protein, have attracted growing interest in drug research by encouraging pharmaceutical companies to design and develop therapeutic products to...
8.
Cordoba K, Jerico D, Sampedro A, Jiang L, Iraburu M, Martini P, et al.
Int Rev Cell Mol Biol
. 2022 Sep;
372:55-96.
PMID: 36064267
Inborn errors of metabolism (IEM) encompass a group of monogenic diseases affecting both pediatric and adult populations and currently lack effective treatments. Some IEM such as familial hypercholesterolemia or X-linked...
9.
Vera-Yunca D, Cordoba K, Parra-Guillen Z, Jerico D, Fontanellas A, Troconiz I
Br J Pharmacol
. 2022 Feb;
179(14):3815-3830.
PMID: 35170015
Background And Purpose: Acute intermittent porphyria (AIP) is a rare disease caused by a genetic mutation in the hepatic activity of the porphobilinogen-deaminase. We aimed to develop a mechanistic model...
10.
Cordoba K, Serrano-Mendioroz I, Jerico D, Merino M, Jiang L, Sampedro A, et al.
Sci Transl Med
. 2022 Jan;
14(627):eabc0700.
PMID: 35020410
Correction of enzymatic deficits in hepatocytes by systemic administration of a recombinant protein is a desired therapeutic goal for hepatic enzymopenic disorders such as acute intermittent porphyria (AIP), an inherited...